Annual report pursuant to Section 13 and 15(d)

Discontinuing Operations (Details Narrative)

v3.23.1
Discontinuing Operations (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 02, 2022
Feb. 28, 2023
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 30, 2022
Disposal Group, Including Discontinued Operation, Assets             $ 2,000,000.0
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents             $ 827
Impairment of intangible assets, indefinite-lived     $ 1,500,000 $ 20,200,000 $ 5,400,000    
Liabilities of discontinuing operations - current       3,522,000 1,219,000 $ 3,522,000  
Amortization of intangible assets         0 713,000  
Cancer Genetics Inc [Member]              
Liabilities of discontinuing operations - current       $ 409,000 267,000 $ 409,000  
Trade Names [Member]              
Impairment of intangible assets, indefinite-lived         500,000    
Customer Relationships [Member]              
Impairment of intangible assets, indefinite-lived         2,700,000    
Goodwill [Member]              
Impairment of intangible assets, indefinite-lived         $ 2,200,000    
Vivo Pharm Pty Ltd [Member]              
Gain (Loss) on Disposition of Assets $ 5,500,000            
[custom:GainLossOnDispositionOfAssetsAdjustment] 5,500,000            
Disposal Group, Including Discontinued Operation, Assets 4,800,000            
Business Exit Costs 400,000            
Disposal Group, Including Discontinued Operation, Liabilities $ 357,000            
Vivo Pharm Pty Ltd [Member] | Subsequent Event [Member]              
[custom:GainLossOnDispositionOfAssetsAdjustment]   $ 300,000